gi

Aric L Gregson

MD FIDSA

Education

1988–1992 **B.A. with Thesis**, *University of California*, Santa Cruz.

Phi Beta Kappa, College Honors, Honors in Biology

1993–1997 M.D., University of California, School of Medicine, Los Angeles.

Alpha Omega Alpha, Letters of Distinction in Doctoring & Pediatrics

1997–1998 Internship, Department of Medicine LAC Harbor-UCLA Medical Center, Torrance.

Internal Medicine

1998–2000 Residency, Department of Medicine LAC Harbor-UCLA Medical Center, Torrance.

Internal Medicine

2001–2003 Clinical Fellowship, Division of Infectious Diseases, Department of Medicine, University of Mary-

land Medical System, Baltimore VA & Shock Trauma, Baltimore.

Infectious Diseases

2003–2005 Vaccinology Fellowship, Malaria Section, Center for Vaccine Development, University of Mary-

land School of Medicine, Baltimore.

Malariology, Clinical Vaccinology

Licensure

1999-present California, A68156, Active.

2001–2007 Maryland, *D57097*, Inactive.

Board Certification

2000–2010 **Diplomate**, American Board of Internal Medicine Internal Medicine.

2003-present Diplomate, American Board of Internal Medicine Infectious Diseases.

2016—present Diplomate, National Board of Physicians and Surgeons, Internal Medicine & Infectious Diseases.

Professional Positions

2020-presen

Senior Infectious Disease Transplant Consultant, Division of Infectious Diseases, Department of Medicine, Loma Linda University School of Medicine, Loma Linda.

Provide consultative services to the LLUMC transplant services, mentoring to faculty, and teaching to resident physicians.

- 2017—present President / Chief Executive Officer, AG Infectious Diseases, Los Angeles. Founded AGID to provide excellence in all aspects of Infectious Diseases.
- 2014–2017 **Health Sciences Associate Clinical Professor of Medicine**, *Division of Infectious Diseases, Department of Medicine*, *UCLA School of Medicine*, Los Angeles.

 Led translational research program investigating alloimmune responses in lung transplant recipients. Consultant for Heart & Lung, Liver, Small Bowel & Pancreas and Stem Cell Transplant Programs, and General ID Teaching Service.
- 2009–2014 **Health Sciences Assistant Clinical Professor of Medicine**, *Divisions of Infectious Diseases & General Internal Medicine*, *Department of Medicine*, *UCLA School of Medicine*, Los Angeles.

 Led translational research program investigating alloimmune responses in lung transplant recipients. Consultant for Heart & Lung, Liver, Small Bowel & Pancreas and Stem Cell Transplant Programs, and General ID Teaching Service.
- 2007–2009 Assistant Clinical Professor of Medicine, Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles.

 Developing translational research program investigating alloimmune responses in lung transplant recipients. Consultant for the Heart & Lung Transplant & Cardiac Assist Device Programs and the General ID Teaching Service.
- Clinical Instructor of Medicine, Division of Infectious Diseases, Department of Medicine, UCLA School of Medicine, Los Angeles.
 Initiated first translational research program in alloimmunity within the Division of Infectious Diseases. Consultant for the Heart & Lung Transplant & Cardiac Assist Device Programs and the General ID Teaching Service.
- 2005–2006 **Consultant, Clinical Vaccinologist**, *PATH's Malaria Vaccine Initiative*, Bethesda.

 RTS,S Malaria Vaccine Program Officer. Overseeing safety in African trails, developing vaccine protocols, EPI integration.
- 2002–2005 Attending Physician & Clinical Instructor, Division of Emergency Medicine, Department of Surgery, University of Maryland School of Medicine & Baltimore VA Medical Center, Baltimore. Emergency medicine practice & resident teaching in metropolitan VA ED with high acuity.
- 2003–2005 **Attending Physician & Clinical Instructor**, *Division of Geographic Medicine*, *Department of Medicine*, *University of Maryland School of Medicine*, Baltimore.
- 2003–2005 **Attending Physician**, *Traveller's Clinic, Department of Medicine, University of Maryland School of Medicine*, Baltimore.
- 2001–2003 **Assistant Clinical Instructor of Medicine**, *Division of Infectious Diseases*, *Department of Medicine*, *University of Maryland Medical System*, Baltimore.
- 2000–2001 Attending Physician, Department of Emergency Medicine, Kaiser Permanente West Los Angeles Medical Center, Los Angeles.

 Emergency medicine practice in busy, metropolitan ED with city 911 traffic & high acuity.
- 2000–2001 Attending Physician, Department of Medicine, Kaiser Permanente Bellflower Medical Center, Bellflower.

 Hospitalist on inpatient medical service.
 - 2000 Attending Physician, Department of Family Medicine, Kaiser Permanente, Harbor City & West Los Angeles.
 Urgent care.
- 1992–1993 **Emergency Medical Technician-D**, *Long Beach Memorial Medical Center*, Long Beach. Medical & cardiac intensive care service.
- 1990–1992 **Emergency Medical Technician-D**, *San Benito County EMS*, Hollister. Emergency ambulance service providing 911 coverage to all of San Benito County.

Professional Activities

- 2020—present **Site Principal Investigator**, *Regeneron R10933-10987-COV-2066*, *Site#840042*, A Master Protocol Assessing Safety and Efficacy of Anti-Spike SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19, Providence Holy Cross Medical Center.
- 2020—present **Site Principal Investigator**, *Novartis MAS825*, A Phase 2, randomized, placebo-controlled, participant and investigator blinded, multi-center study to assess efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function, Providence Holy Cross Medical Center.
- 2020—present **Site Principal Investigator**, *EAP Convlaescent Plasma*, Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 (NCT 04338360), Providence Holy Cross Medical Center.
- 2020-present Medical Director, Infection Prevention, Providence Holy Cross Medical Center, Mission Hills.
- 2019—present Director, Antimicrobial Stewardship, Providence Holy Cross Medical Center, Mission Hills.
- 2018–2019 **CME Committee**, *Providence Saint Joseph Medical Center*, Burbank.
- 2017—present **Expert Reviewer**, *Medical Board of California*, Los Angeles. Infectious Diseases area of specialization
- 2017—present BAL Standardization Subgroup 5, International Society for Heart & Lung Transplantation, Los Angeles.

Development of a consensus statement on Standardization of Bronchoalveolar Lavage in Lung Transplantation. Subgroup 5 is focused on research uses of bronchoalveolar lavage fluid.

- 2016–2020 Basic Science Council Liaison to the Infectious Diseases Council, International Society for Heart & Lung Transplantation, Los Angeles.
- 2016–2017 **Site Co-Investigator**, *Chimerix 351*, An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease, UCLA Medical Center.
- 2015–2017 **Site Co-Investigator**, *Merck MK-8228*, MK-8228 vs. Placebo in Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients, UCLA Medical Center.
- 2015–2017 **Site Co-Investigator**, *REACT*, A Prospective Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Events—Assessed by a CMV-specific T-SPOT Assay, UCLA Medical Center.
- 2014–2017 **Site Co-Investigator**, *Chimerix 333*, CMX001 Registry: A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in CMX001, UCLA Medical Center.
- 2014–2017 Planning & Land Use Management Committee Member, West Los Angeles Sawtelle Neighborhood Council, Los Angeles.
 Was awarded Certificate of Appreciation by Councilman Bonin.
- 2013–2017 Member, P & T Antibiotic Subcommittee, UCLA Medical Center, Los Angeles.
- 2013–2014 **Site Co-Investigator**, *CMX301XX-CMX001*, UCLA Medical Center & Chimerix, Incorporated, Los Angeles.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R⁺) Hematopoietic Stem Cell Transplant Recipients, NCT01769170.

- 2012–2014 Clinical Collaborator/Adviser, Amanda Silberstein, PhD Student, UCLA Chemistry Department, Neil Garg Laboratory, Organic Chemistry, Los Angeles.
 - The Development of Iron-Catalyzed Cross-Coupling Reactions and their Application to the Synthesis of Anti-Malarial Compounds.
- 2012–2017 **Site Co-Investigator**, *CAPSIL*, UCLA Medical Center & NIH/DMID.

 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R⁻D⁺ Liver Transplant Recipients, NCT01552369.

- 2012–2015 **Site Co-Principal Investigator**, *DEFLECT-1*, UCLA Medical Center & Optimer Pharmaceuticals, Inc, Los Angeles.
 - A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation, NCT01691248.
- 2012–2015 **Member, Expert Fungal Panel**, *Scientific Council on Infectious Diseases*, International Society for Heart & Lung Transplantation.
- 2012–2013 **Site Co-Investigator**, *Maribavir/Protocol 1263-202*, UCLA Medical Center & ViroPharma Incorporated, Los Angeles.

A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients, NCT01611974.

- 2012–2013 Member, Infectious Diseases Management Program, UCLA Medical Center, Los Angeles.
- 2012—present Associate Editor, PLos Neglected Tropical Diseases.
- 2012–2017 Editorial Board, Dataset Papers in Medicine.
- 2012–2017 **Principal Investigator**, *CDC IND for Pentostam*, UCLA Medical Center, Los Angeles. Use of sodium stibogluconate for the treatment of cutaneous and mucocutaneous leishmania.
- 2011–2019 **Infectious diseases outcomes investigations**, *UCLA Medical Center*, Los Angeles.

 Utilize hospital-wide data to investigate selective pressure in development of and outcomes for various hospital related infections at UCLA. Focused on VRE & CRE blood stream infections in collaboration with Dr. James McKinnell (LA BioMed & UCLA CTSI).
- 2010–2014 At-Large Representative, West Los Angeles Neighborhood Council, Los Angeles.
- 2008—present **Medical Advisory Committee**, Fertility Cryobank, LLC, Los Angeles.

ternational meetings & writing final manuscript.

- 2007-present Academic Editor, PLoS ONE.
- 2007–2017 Lung Transplant Executive Committee, UCLA Medical Center, Los Angeles.
- 2007–2009 Heart Transplant Executive Committee, UCLA Medical Center, Los Angeles.
- 2007–2008 Immune profiling orthotopic heart transplant recipients, UCLA & Stanford School of Medicine, Los Angeles & Stanford.

Utilize phosphoproteomic-flow cytometry in collaboration with Drs. Daniel Cruz (UCLA Cardiology) & Peter Krutzik (Stanford-Nolan Lab).

- 2006–2009 Morbidity & Mortality Committee, UCLA Department of Medicine, Los Angeles.
- 2005–2006 **Develop RTS,S phase 2 malaria vaccine trials**, *PATH'S Malaria Vaccine Initiative*, Bethesda.

 Development of malaria vaccine testing sites throughout Africa, clinical vaccine development plans, trial design & protocol development in collaboration with GSK Biologicals. Interaction with multiple IRBs & DSMBs, & medical safety review of ongoing trials.
- 2002–2004 **Malaria vaccine trial site preparation**, *Center for Vaccine Development (CVD)*, *University of Bamako, WRAIR & GSK Biologicals*, Bandiagara, Mali.

 Preparation of phase 1/1b malaria vaccine site in West Africa. Co-investigator involved in trial design, pro-

tocol & SOP development, physician training, study initiation & manuscript preparations.

- 2002–2005 Acting principal investigator Phase 1 malaria vaccine trial, CVD & DMID, Baltimore.

 Responsibilities included all aspects of trial management from study design, protocol development, SOP & case report form creation, database development, IRB submissions, reporting to DSMB, interaction with funding agency NIAID/DMID, consenting & assessing volunteers, study analysis, reporting trial results at in-
- 2002–2003 Clinical trial site preparation, CVD & University of Bamako, Bancoumana, Mali.

 Co-PI on epidemiological study of drug-resistant malaria transmission. Responsible for study design, negotiating collaboration of multiple disciplines in Malian medical school, training of study physicians, analysis/writing of results & presenting at international meetings.

2000 Clinical Malariology, Shoklo Malaria Research Unit, Welcome Trust-Mahidol University, Mae Sod. Thailand.

Clinical focus on management of malaria and tuberculosis in resource-poor area, brief introduction to malaria field trials with Dr. François Nosten.

1999 Clinical Tropical Medicine, Programa de Epidemiología y Control de las Enfermedades Tropical (PECET) Universidad de Antioquía & Secretaria de Salud Amazonas, Medellín, Leticia, Tarapacá, Colombia.

Clinical program in management of tropical diseases and the practice of tropical medicine, with emphasis on malaria, leishmania and endemic fungi.

1996 **Epidemiology Elective for Medical Students**, *Centers for Disease Control & Prevention, Hepatitis Division*, *NCID*, Atlanta.

Investigation of tornado devastation in Arkansas.

1996 **Tropical Medicine & Mycology Elective**, *Corporación para Investigaciones Biológicas (CIB)*, Medellín, Colombia.

Clinical introduction to tropical medicine with Drs. Angela & Marcos Restrepo.

- 1996 Instructor, Doctoring IV UCLA School of Medicine, Los Angeles.
- 1996 **Diagnostic Parasitology Independent Study**, *UCLA Clinical Parasitology Laboratory & UCLA Travel Clinic (Dr. Claire Panosian)*, Los Angeles.

Professional Memberships

2013—present Infectious Diseases Society of America, Fellow.

2010-2016 Randonneurs USA, #6744.

2006—present American Society of Transplantation.

2006—present International Society for Heart & Lung Transplantation.

2000-2007 American Society of Tropical Medicine & Hygiene.

Languages

English, Native tongue.

Spanish, Medical and conversational, fair writing and reading.

German, Limited reading, writing and speaking.

French, Limited conversational speaking.

Ad Hoc Reviewer

Lancet Respiratory Medicine, Annals of Internal Medicine, Clinical Infectious Diseases, Journal of Infectious Diseases, Journal of the American Medical Association, Vaccine, American Journal of Transplantation, Journal of Heart & Lung Transplantation, Transplantation, Transplantation, Transplantation, PLos Neglected Tropical Diseases, American Journal of Tropical Medicine and Hygiene, Molecular and Biochemical Parasitology, ACP PIER Modules, Clinical Dermatology.

Honors and Special Awards

- 2019 **Selected to Participate**, *Annual Customer Photography Show*, Blue Moon Camera & Machine, Portland, OR.
- 2019 Invited Lecturer, "Transplant ID: Year in Review", ASM Microbe, San Francisco, CA.
- 2018 **Selected to Participate**, *Annual Customer Photography Show*, Blue Moon Camera & Machine, Portland, OR.
- 2018 Invited Lecturer, "Transplant ID: Year in Review", ASM Microbe, Atlanta, GA.
- 2017 Election to Fellow, Research Track, Infectious Diseases Society of America.

- 2017 **Invited Lecturer**, "When the Rubber Hits the Road: Case and Panel Discussions", ISHLT 2017 Academy: Core Competencies for Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support, San Diego, CA.
- 2016 **Invited Lecturer**, "The Role of Bacterial Infection in Bronchiolitis Obliterans Syndrome in Lung Transplantation", Inaugural Meeting, ASM Microbe (ASM/ICACC 2016), Boston, MA.
- 2014 **Certificate of Appreciation**, *Outstanding Contribution to Lecture Series*, Medical Engineering Department, Engineering & Applied Sciences, California Technical Institute, Pasadena, CA.
- 2014 **Certificate of Recognition**, *Outstanding Service to the City of Los Angeles, 11th District*, Councilman Mike Bonin, Los Angeles, CA.
- 2014 Invited Lecturer, "Treatment of Invasive Fungal Infections: State of the Art. Consensus Guidelines & Recommendations ISHLT Fungal Expert Panel", International Society for Heart & Lung Transplantation 34th Annual Meeting, San Diego, CA.
- 2013 **Invited Lecturer**, "The Role of Bacterial Infection & Colonization on Chronic Allograft Dysfunction", International Society for Heart & Lung Transplantation 33rd Annual Meeting, Montréal, Canada.
- 2011 Clinical and Health Services Research Award, Junior Faculty, Department of Medicine Research Day, UCLA Department of Medicine, Los Angeles, CA.
- Visiting Professor, Asahi General Hospital, Asahi, Japan.
 Teaching Medical residents Internal Medicine with an emphasis on Infectious Diseases.
- 2005 Burroughs Welcome Fund-Howard Hughes Medical Institute Course in Scientific Management, *BWF-HHMI*, Bethesda, MD.
- 2001 **Malaria Research Training Program**, Center for Vaccine Development, University of Maryland School of Medicine & Fogarty International Center, Mali.
- 1997 Alpha Omega Alpha, Letter of Distinction in Pediatrics & Doctoring, UCLA School of Medicine, Los Angeles, CA.
- 1996 Marietta Voge Memorial Fund in Tropical Medicine, UCLA School of Medicine, Colombia.
- 1992 Phi Beta Kappa, Honors in Biology, College Honors, University of California, Santa Cruz, CA.

Research Grants and Fellowships Received

Investigator Initiated Proposal	PI EY Cheng, OneLegacy Foundation	Completed 01/2017– 12/2017	"Understanding the Role of B Lymphocytes in Intestinal Transplant Graft Rejection"
R01 HL112990 Investigator Initiated Award	PI J Belperio, NIH/NHLBI	Completed 05/15/12– 02/28/17	"Immune Mechanisms of Alloinjury" Human and pre-clinical murine studies investigating the role of lymphocytes in development of BOS.
K23 HL102220 Career Development Award	PI A Gregson, NIH/NHLBI	Completed 12/1/10– 05/30/16	"Role of T Regulatory Cells in Preventing Human BOS" Evaluation of intragraft and circulating lymphocytes and BOS outcomes.
Pilot and Feasibility Award	PI A Gregson, Cystic Fibrosis Foundation	Completed 4/1/10— 3/31/12	"Harnessing T Regulatory Cells to Prevent Chronic Lung Allograft Rejection." Translational lung transplant studies focusing on intragraft lymphocytes and chemokines.

Stein Oppen- heimer Endowment Award	PI A Gregson, Gerald Oppenheimer Foundation		"Protection Against Development of BOS by CCR7 $^+$ T Regulatory Cells." Focused evaluation of intragraft CCR7 $^+$ Treg & BOS outcomes.
Fellowship in Tropical Disease Research	PI A Gregson, BWF/ASTMH		"Burroughs Wellcome Fund-American Society of Tropical Medicine & Hygiene Post-Doctoral Fellowship in Tropical Disease Research". Research funding and partial salary support for malaria transmission epidemiology study in Mali, West Africa.
T32 AI-07524	PI M Levine, NIH/NRSA	7/1/01- 6/30/06	T32 postdoctoral fellowship training grant, which provided salary support for my fellowship at the CVD.

Lectures

March 2020	The Novel Coronavirus SARS-CoV-2, Adult Congenital Heart Association Webinar Series,
	Broadcast on Zoom with \approx 2,000 viewers and then on YouTube with \approx 10,000 views, Los Angeles.

- December *Malaria, Clinical Management*, *UCLA Global Medicine Core Lecture Series*, UCLA School of 2019 Medicine, Los Angeles.
- September *Typhoid Fever in an Age of Resistance*, *Tropical Medicine Update for Savvy Clinicians*, UCLA 2019 School of Medicine, Los Angeles.
- September Case Studies in Severe Malaria, Tropical Medicine Update for Savvy Clinicians, UCLA School of 2019 Medicine, Los Angeles.
- April & *Malaria, Clinical Management*, *UCLA Global Medicine Core Lecture Series*, UCLA School of September Medicine, Los Angeles.

 2018
- April 2017 *Common Infections in Oncology Patients: Neutropenic Complications*, CME Lecture Program, Providence Saint Joseph Medical Center, Burbank.
- July 2016 Infectious Prophylaxis Following Lung Transplantation: A Hopeful Journey, Integrated Infectious Diseases Fellowship Lectures, West Los Angeles VA Medical Center, Los Angeles.
- October 2015 *Infectious Diseases for Medical Engineers*, *Medical Engineering Department, Engineering & Applied Sciences*, California Technical Institute, Pasadena.
- August 2015 Infectious Prophylaxis Following Lung Transplantation: A Hopeful Journey, Integrated Infectious Diseases Fellowship Lectures, West Los Angeles VA Medical Center, Los Angeles.
 - November *Infectious Diseases for Medical Engineers*, *Medical Engineering Department, Engineering & Applied Sciences*, California Technical Institute, Pasadena.
- August 2014 *Updates on Infectious Diseases of the Liver for Surgeons*, UCLA Department of Surgery Grand Rounds, UCLA Medical Center, Los Angeles.
 - July 2014 *CMV After Liver Transplantation*, UCLA Liver Unit Nursing Educational Rounds, Take Five!, UCLA Medical Center, Los Angeles.
 - May 2014 Infectious Prophylaxis Following Lung Transplantation: A Hopeful Journey, Harbor-UCLA Department of Medicine Grand Rounds, Harbor-UCLA Medical Center, Torrance.
 - November Infections Following Organ Transplantation, Invited Lecture for the West Hills Hospital Grand 2013 Rounds, West Hills Hospital and Medical Center, West Hills.
 - November *Malaria is Beautiful: Disaster Avoidance for the Clinical Microbiologist*, *Invited Lecture for the UCLA Clinical Microbiology Laboratory*, UCLA Medical Center, Los Angeles.
- September *Malaria, Clinical Management*, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA 2012 School of Medicine, Los Angeles.

- June 2012 Infectious Prophylaxis Following Lung Transplantation: A Hopeful Journey, Harbor-UCLA Infectious Diseases Grand Rounds, Harbor-UCLA Medical Center, Torrance.
- June 2011 *Pulmonary Infections Following Thoracic Organ Transplantation*, Harbor-UCLA Pulmonary & Critical Care Grand Rounds, Harbor-UCLA Medical Center, Torrance.
- May 2011 Phenotypically Distinct T Cell Subsets are Involved in the Pathogenesis of Lung Allograft Dysfunction, UCLA Pulmonary & Critical Care Grand Rounds, UCLA School of Medicine, Los Angeles.
- November Lung Transplantation from the Eye of an Infectious Diseases Doctor, Harbor-UCLA Infectious 2009 Diseases Grand Rounds, Harbor-UCLA Medical Center, Torrance.
- June 2009 *Viral Hemorrhagic Fevers*, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA School of Medicine, Los Angeles.
 - January *Malaria, Clinical Management*, UCLA Division of Infectious Diseases Core Lecture Series, UCLA 2009 School of Medicine, Los Angeles.
- December Clinical Microbiology Review, Part I, UCLA Division of Infectious Diseases Core Lecture Series, 2008 UCLA School of Medicine, Los Angeles.
- April 2008 *Dengue Fever, Clinical Introduction*, UCLA Division of Infectious Diseases Core Lecture Series, UCLA School of Medicine, Los Angeles.
- February *Unique BALF Effector Lymphocyte Populations Correlate with Lung Allograft Rejection*, 2008 *Lung Transplant Core Research Meeting*, UCLA School of Medicine, Los Angeles.
- January *Malaria, Clinical Management*, UCLA Division of Infectious Diseases Core Lecture Series, UCLA 2008 School of Medicine, Los Angeles.
- August 2007 *Malaria: From var to Vaccine*, *Harbor-UCLA Infectious Diseases Grand Rounds*, Harbor-UCLA Medical Center, Torrance.
 - December Lung Transplantation: From the Eyes of Infectious Diseases, Combined Pediatric/Adult In-2007 fectious Diseases Grand Rounds, UCLA School of Medicine, Los Angeles.
 - June 2007 *Pulmonary Infections Post-Solid Organ Transplantation*, Harbor-UCLA Pulmonary Grand Rounds, Harbor-UCLA Medical Center, Torrance.
 - June 2007 *Tuberculosis*, UCLA Division of Infectious Diseases Core Lecture Series, UCLA School of Medicine, Los Angeles.
- March 2007 **Discussion of Opportunistic Infections in the Setting of Renal Transplantation**, *Division of Nephrology Grand Rounds*, UCLA School of Medicine, Los Angeles.
- March 2007 Interesting Infectious Pulmonary Cases, 5^{th} UCLA Pulmonary and Critical Care Medicine Update, Santa Monica.
 - February *Malaria, Clinical Management*, *UCLA Division of Infectious Diseases Core Lecture Series*, UCLA 2007 School of Medicine, Los Angeles.
- October 2006 **Keynote Speaker**, *Department of Medicine Morbidity & Mortality Conference*, UCLA School of Medicine, Los Angeles.
 - June 2006 **Syphilis: Pathogenesis of Lues**, Combined Pediatric/Adult Infectious Diseases Grand Rounds, UCLA School of Medicine, Los Angeles.
 - April 2006 *Malaria* var *Genes*, *Combined Pediatric/Adult Infectious Diseases Grand Rounds*, UCLA School of Medicine, Los Angeles.
 - 2004 Phase I trial of a malaria vaccine consisting of hepatitis B virus core particle containing repeat and T-cell epitopes of the P. falciparum CS protein, CVD Mini-Presentations, 2004 Frontiers in Vaccinology, University of Maryland School of Medicine, Baltimore.
 - 2003 *Mosquitoes, Oocysts, Gametes and Us*, *Pathogenesis Conference, Division of Infectious Diseases*, University of Maryland School of Medicine, Baltimore.

- 2002 *Malaria, the Placenta, and Unpleasant Interactions*, *Pathogenesis Conference, Division of Infectious Diseases*, University of Maryland School of Medicine, Baltimore.
- 2000 World Bank and International Health, Housestaff Lecture Series Department of Medicine, LAC Harbor-UCLA Medical Center, Torrance.
- 1999 *Pheochromocytoma*, *Grand Rounds*, *Division of Endocrinology, Department of Medicine*, LAC Harbor-UCLA Medical Center, Torrance.
- 1998 Food-Borne Illness: Epidemiological Aspects and Recent Trends Within Developing World, Housestaff Lecture Series, Department of Medicine, LAC Harbor-UCLA Medical Center, Torrance.
- 1998 Impotence and Male Sexual Dysfunction, Ambulatory Care Lecture Series, Department of Medicine, LAC Harbor-UCLA Medical Center, Torrance.

Publications—Research Papers—Peer Reviewed

- [1] Sokolove PE, Lee BS, Krawczyk JA, Banos PT, **Gregson AL**, Boyce DM, Lewis RJ. Implementation of an Emergency Department Triage Procedure for the Detection and Isolation of Patients at High Risk for Having Pulmonary Tuberculosis. *Annals of Emergency Medicine* **2000** Apr; 35(4):327–336. EFn: 2.1 Al: 1.6 JIF: 4.695 Google Scholar Cites: 30 Scopus Cites: 14
- [2] **Gregson AL**, Plowe CV. Mechanisms of Resistance of Malaria Parasites to Antifolates. *Pharmacological Reviews* **2005** Mar; 57(1):118–145. EFn: 1.9 Al: 8.1 JIF: 17.099 Google Scholar Cites: 466 Scopus Cites: 218
- [3] Thera MA, Doumbo OK, Coulibali D, et. al. Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLoS Clinical Trials. 2006 Nov 24; 1(7):e34. Google Scholar Cites: 77
- [4] Thera MA, Doumbo OK, Coulibali D, et. al. Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLoS ONE 2008 Jan 23; 3(1):e1465.

 PMC2186380 EFn: 128 Al: 1.4 JIF: 3.234 Google Scholar Cites: 101 Scopus Cites: 54
- [5] **Gregson AL**, Oliveira G, Othoro Watta C, Calvo-Calle JM, Thorton GB, Nardin E, Edelman R. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of *Plasmodium falciparum* circumsporozoite protein. *PLoS ONE* **2008** Feb 6; 3(2):e1556. PMC2216688 EFn: 128 Al: 1.4 JIF: 3.234 ISI Cites: 18 Google Scholar Cites: 47 Scopus Cites: 24
- [6] **Gregson AL**, Hoji A, Saggar R, Ross DJ, Kubak BM, Jamieson BD, Weigt SS, Lynch III JP, Ardehali A, Belperio JA, Yang OO. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. *Transplantation* **2008** Apr 15; 85(7):1056–1059. PMC2744369 EFn: 4.3 Al: 1.2 JIF: 3.828 Google Scholar Cites: 48 Scopus Cites: 32
- [7] Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, **Gregson AL**, Kubak B, Fishbein MC, Saggar R, Ross DJ, Lynch III JP, Zisman DA, Belperio JA. Altered Levels of CC Chemokines during Pulmonary CMV Predict Mortality and Mortality Due to BOS Post-Lung Transplantation. *American Journal of Transplantation* **2008** July; 8(7):1512–1522. PMC2760345 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 61 Scopus Cites: 31
- [8] Saggar R, Ross DJ, Saggar R, Zisman DA, **Gregson A**, Lynch JP, Keane MP, Weigt SS, Ardehali A, Kubak B, Lai C, Elashoff D, Fishbein MC, Wallace WD, Belperio JA. Pulmonary Hypertension Associated With Lung Transplantation Obliterative Bronchiolitis Is Due To Vascular Remodeling of the Allograft. *American Journal of Transplantation* **2008** July; 8(9):1921–1930. PMC4207285 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 29 Scopus Cites: 14
- [9] Kubak BM, **Gregson AL**, Pegues DA, Leibowitz MR, Carlson M, Marelli D, Patel J, Laks H, Kobashigawa JA. Use of Hearts Transplanted From Donors With Severe Sepsis and Infectious

- Deaths. *Journal of Heart and Lung Transplantation* **2009** March; 28(3):260–265. © EFn: 2.5 Al: 1.4 JIF: 6.650 Google Scholar Cites: 27 Scopus Cites: 10
- [10] Nickerson DW, Presson AP, Weigt SS, **Gregson A**, Belperio JA, Gomperts BN. Quantification of cytokeratin 5 mRNA expression in the circulation of healthy human subjects and after lung transplantation. *PLoS ONE* **2009**; 4(6):e5925. PMC2691992 EFn: 128 Al: 1.4 JIF: 3.234
- [11] Weigt SS, Elashoff RM, Huang C, Ardehali A, **Gregson AL**, Kubak B, Fishbein MC, Saggar R, Keane MP, Saggar R, Lynch JP, Zisman DA, Ross DJ, Belperio JA. Aspergillus Colonization of the Lung Allograft is a Risk Factor for Bronchiolitis Obliterans Syndrome. *American Journal of Transplantation* **2009** May; 9(8):1903 1911. PMC4214373 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 172 Scopus Cites: 63
- [12] Kun H, Moore A, Mascola L, *et. al.*. Transmission of Trypanosoma cruzi by Heart Transplantation. *Clinical Infectious Diseases*. **2009** Jun 1; 48(11):1534–40. EFn: 14.2 Al: 3.3 JIF: 8.886 Google Scholar Cites: 117 Scopus Cites: 53
- [13] Wang TF, Wang T, Altman R, Eshaghian P, Lynch JP, Ross DJ, Belperio JA, Weigt SS, Saggar R, **Gregson A**, Kubak B, Saggar R. Periostitis Secondary to Prolonged Voriconazole Therapy in Lung Transplant Recipients. *American Journal of Transplantation*. **2009** Oct 21; 9(12):2845–2850.

 © EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 68 Scopus Cites: 29
- Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, Kubak B, Ardehali A, Derhovanessian A, Clements PJ, Shapiro S, Hunter C, **Gregson A**, Fishbein MC, Lynch JP, Ross DJ, Saggar R. Systemic Sclerosis and Bilateral Lung Transplantation: A Single Center Experience. *European Respiratory Journal*. **2010** Mar 29; 36(4):893–900. PMC2921556 EFn: 6.2 Al: 2.1 JIF: 7.636 Google Scholar Cites: 105 Scopus Cites: 43
- [15] Beavogui A, Djimdé AA, **Gregson AL**, Dao A, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Kone A, Toure AM, Plowe CV, Doumbo OK. Low Infectivity of Post-Sulfadoxine-Pyrimethamine *Plasmodium falciparum* Gametocytes to *Anopheles gambiae* in Mali. *International Journal for Parasitology* **2010** May 8; 40(10):1213–1220. PMC3571761 EFn: 1.7 Al: 1.2 JIF: 3.872 Google Scholar Cites: 31 Scopus Cites: 16
- [16] **Gregson AL**, Hoji A, Palchevskiy V, Hu S, Weigt SS, Liao E, Derhovanessian A, Saggar R, Song S, Elashoff R, Yang OO, Belperio JA. Protection Against Bronchiolitis Obliterans Syndrome is Associated with Allograft CCR7+CD45RA- T Regulatory Cells. *PLoS ONE* **2010** Jun 29; 5(6):e11354.

 PMC2894051 EFn: 128 Al: 1.4 JIF: 3.234 Google Scholar Cites: 30 Scopus Cites: 14
- Zaghi D, Panosian C, Gutierrez M, **Gregson A**, Taylor E, Ochoa MT. New World Cutaneous Leishmaniasis: Current Challenges in Diagnoses and Parenteral Therapy. *Journal of the American Academy of Dermatology* **2011** Mar; 64(3):587–592. EFn: 3.3 Al: 1.4 JIF: 4.449 Google Scholar Cites: 18 Scopus Cites: 5
- [18] Huang HC, Weigt SS, Derhovanessian A, et. al.. Non-Tuberculous Mycobacterium Infection after Lung Transplantation is Associated with Increased Mortality. Journal of Heart and Lung Transplantation 2011 Jul; 30(7):790–8. PMC3942162 EFn: 2.5 Al: 1.4 JIF: 6.650 Google Scholar Cites: 71 Scopus Cites: 16
- [19] Weigt SS, Derhovanessian A, Liao E, Hu S, **Gregson AL**, Kubak BM, Saggar R, Saggar R, Plachevskiy V, Fishbein MC, Lynch JP, Ardehali A, Ross DJ, Elashoff RM, Belperio JA. CXCR3 Chemokine Ligands during Respiratory Viral Infections Predict Progressive Lung Allograft Dysfunction. *American Journal of Transplantation* **2012** Feb; 12(2):477–484. PMC3833088 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 39 Scopus Cites: 11
- [20] Shino MY, Weigt SS, Saggar R, Elashoff D, Derhovanessian A, **Gregson AL**, Saggar R, Reed EF, Kubak BM, Lynch JP, Belperio JA, Ardehali A, Ross DJ. Usefulness of immune monitoring

in lung transplantation using adenosine triphosphate production in activated lymphocytes. *The Journal of Heart and Lung Transplantation* **2012** Sep; 31(9):996–1002. PMC4204735 EFn: 2.5 Al: 1.4 JIF: 6.650 Scopus Cites: 5

- [21] Gregson AL, Wang X, Weigt SS, Elashoff R, Lynch JP III, Ross DJ, Kubak BM, Saggar R, Ardehali A, Li G, Belperio J. Interaction Between Pseudomonas and CXC Chemokines Increases Risk of BOS and Death in Lung Transplantation *American Journal of Respiratory and Critical Care Medicine* 2013 Mar; 187(5):518–526. PMC3733405 EFn: 10.5 Al: 3.9 JIF: 12.996 Google Scholar Cites: 56 Scopus Cites: 5
- [22] Weigt SS, Copeland CAF, Derhovanessian A, Shino MY, Davis WA, Snyder LD, **Gregson AL**, Saggar R, Lynch JP III, Ross DJ, Ardehali A, Elashoff RM, Palmer SM, Belperio JA. Colonization with Small Conidia Aspergillus Species Is Associated with Bronchiolitis Obliterans Syndrome: A Two-Center Validation Study. *American Journal of Transplantation* **2013** Apr; 13(4):919–927. PMC3618528 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 64 Scopus Cites: 10
- [23] Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggar R, Sayah DM, **Gregson AL**, Fishbein MC, Ardehali A, Ross DJ, Lynch JP 3rd, Elashoff RM, Belperio JA. CXCR3 Ligands Are Associated with the Continuum of Diffuse Alveolar Damage to Chronic Lung Allograft Dysfunction. *American Journal of Respiratory and Critical Care Medicine* **2013** Nov; 9(1):1117–1125. PMC3863740 EFn: 10.5 Al: 3.9 JIF: 12.996 Google Scholar Cites: 35 Scopus Cites: 6
- Injean P, Hsiue PP, Vangala S, Miller LG, Benharash P, Brindis RG, McKinnell JA, **Gregson AL**. Survey of Pre-Operative Infection Prevention for CABG Procedures. *Infection Control & Hospital Epidemiology* **2014** Jun; 35(6):736-737. PMC4169282 EFn: 2.7 Al: 1.5 JIF: 4.175 Google Scholar Cites: 7 Scopus Cites: 2
- [25] Hsiue PP, **Gregson AL**, Injean P, Vangala S, Fonner E, Brindis RG, Parker J, Shemin RJ, Shahian DM, Miller LG, Benharash P, McKinnell JA. Antibiotic Selection for Coronary Artery Bypass Graft Procedures in an Era of Resistance. *Infection Control & Hospital Epidemiology* **2014** Jun; 35(6):737-740. PMC4169278 EFn: 2.7 Al: 1.5 JIF: 4.175 Scopus Cites: 0
- [26] **Gregson AL**, Wang X, Injean P, Weigt S, Shino M, Sayah D, DerHovanessian A, Lynch JP, Ross DJ, Saggar R, Ardehali A, Li G, Elashoff R, Belperio JA. Staphylococcus via an Interaction with the ELR⁺ CXC Chemokine ENA-78 is Associated with BOS. *American Journal of Transplantation* **2015** Mar; 15(3):792–799. PMC4336208 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 12 Scopus Cites:
- [27] Humphries R, Yang S, Hemarajata P, Ward K, Hindler J, Miller SC, **Gregson A**. First Report of Ceftazidime-Avibactam Resistance in a KPC-3 Expressing Klebsiella pneumoniae. *Antimicrobial Agents and Chemotherapy* **2015** Oct; 59(10):6605-6607. EFn: 10.4 Al: 1.4 JIF: 4.476 Google Scholar Cites: 135 Scopus Cites: 1
- [28] Gregson AL, Hoji A, Injean P, Poynter ST, Briones C, Palchevskiy V, Weigt SS, Shino M, Derhovanessian A, Sayah D, Saggar R, Ross D, Ardehali A, Lynch III JP, Belperio JA. Altered Exosomal RNA Profiles in Bronchoalveolar Lavage from Lung Transplants with Acute Rejection. *American Journal of Respiratory and Critical Care Medicine* 2015 Dec; 192(12):1490–1503. EFn: 10.5 Al: 3.9 JIF: 12.996 Google Scholar Cites: 30 Scopus Cites: 1

(See accompanying Editorial by Lama VN. Peering into a Rejecting Lung: Can Bronchoalveolar Lavage Exosomes Provide Novel Insights? *American Journal of Respiratory and Critical Care Medicine* **2015** Dec; 192(12):1413–1414. (4)

DerHovanessian A, Weigt SS, Palchevskiy V, Shino MY, Sayah DM, **Gregson AL**, Noble PW, Palmer SM, Fishbein MC, Kubak BM, Ardehali A, Ross DJ, Saggar R, Lynch JP, Elashoff RM, Belperio JA. The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome. *American Journal of Transplantation* **2016** Feb; 16(2):640–649.

- Sole A, Alexander B, Aslam S, Avery R, Benden C, Billaud E, Chambers D, Danziger-Isakov L, Fedson S, Gould K, **Gregson A**, Grossi P, Hadjiliadis D, Hopkins P, Luong ML, Marriott D, Monforte V, Muñoz P, Pasqualotto A, Roman A, Silveira F, Teuteberg J, Weigt S, Zaas A, Zuckerman A, Morrissey O. The 2015 International Society for Heart and Lung Transplantation Guidelines for the Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients: Executive Summary. *Journal of Heart and Lung Transplantation* **2016** Mar; 35(3):261–282. EFn: 2.5 Al: 1.4 Google Scholar Cites: 70
- [31] DerHovanessian A, Todd JL, Zhang A, Li N, Mayalall A, Finlen Copeland CA, Shino M, Pavlisko EN, Wallace WD, **Gregson A**, Ross DJ, Saggar R, Lynch JP 3rd, Belperio J, Snyder LD, Palmer SM, Weigt SS. Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients. *Annals of the American Thoracic Society* **2016** May; 13(5):627-35. Google Scholar Cites: 14
- Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, Weigt S, Charan D, Abtin F, Johannes J, Derhovanessian A, Conklin J, Ghassemi K, Khanna D, Siddiqui O, Ardehali A, Hunter C, Kwon M, Biniwale R, Lo M, Volkmann E, Torres Barba D, Belperio JA, Sayah D, Mahrer T, Furst DE, Kafaja S, Clements P, Shino M, **Gregson A**, Kubak B, Lynch JP 3rd, Ross D, Saggar R. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. *Annals of the American Thoracic Society* **2016** Jun; 13(6):793–802.
- Allyn RR, Duffy EL, Humphries RH, Injean P, Weigt SS, Saggar R, Shino MY, Lynch III JP, Ardehali A, Belperio JA, Tseng CH, Kubak B, MD, Ross DJ, **Gregson AL**. Graft Death and CLAD Onset is Hastened by Viral Pneumonia After Lung Transplantation. *Transplantation* 2016 Nov; 100(11):2424–2431. EFn: 4.3 Al: 1.2 JIF: 3.69 Google Scholar Cites: 32 (See accompanying Editorial by Snyder LD. It is Not the Flicker but the Fire: Severity Matters in Viral infections After Lung Transplant. *Transplantation* 2016 Nov; 100(11):2248.
- Weigt SS, Wang X, Palchevskiy V, **Gregson AL**, Patel N, Derhovanessian A, Shino MY, Sayah DM, Birjandi S, Lynch III JP, Saggar R, Ardehali A, Ross DJ, Palmer SM, Elashoff D, Belperio JA. Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction. *PLoS ONE* **2017** Jan; 12(1):e0169894. EFn: 128 Al: 1.4 JIF: 3.234 Google Scholar Cites: 15
- Injean P, Eells SJ, Wu H, McElroy I, **Gregson AL**, McKinnell JA. Systematic Review and Meta-Analysis of the Data Behind Current Recommendations for Corticosteroids for Non-HIV Related PCP; Knowing When You Are on Shaky Foundations. *Transplantation Direct* **2017** Mar; 3(3):e137.
- [36] Shino MY, Weigt SS, Li N, Derhovanessian A, Sayah DM, Huynh RH, Saggar R, **Gregson AL**, Ardehali A, Ross DJ, Lynch III JP, Elashoff RM, Belperio JA. Impact of Allograft Injury Time-of-Onset on the Development of Chronic Lung Allograft Dysfunction after Lung Transplantation. *American Journal of Transplantation* **2016** May; 17(5):1294–1303. EFn: 5.9 Al: 2.0 JIF: 5.669
- [37] Shino MY, Weigt SS, Li N, Palchevskiy V, Derhovanessian A, Saggar R, Sayah DM, Huynh RH, Gregson AL, Fishbein MC, Ardehali A, Ross DJ, Lynch III JP, Elashoff RM, Belperio JA. The Prognostic Importance of CXCR3 Chemokine during Organizing Pneumonia on the Risk of Chronic Lung Allograft Dysfunction after Lung Transplantation. *PLoSONE* 2017 Jul; 12(7):e0180281.
- [38] Gaut D, Cone B, **Gregson AL**, Agopian VG. A Case of Gastrointestinal Mucormycosis following Orthotopic Liver Transplantation Presenting as a Femoral Nerve Palsy. *Transplantation Proceedings* **2017** Sep; 49(7):1608–1614.
- [38] Hemarajata P, Amick T, Yang S, **Gregson AL**, Holzmeyer C, Bush K, Humphries RM. Selection of Hyperproduction of SME-1 and AmpC in a Carbapenem-Resistant *Serratia marcescens* During

Antibiotic Therapy. *Journal of Antimicrobial Therapy* **2018** May; 73(5):1256–1262.
Google Scholar Cites: 5

- [39] Linfield RY, Campeau S, Injean P, **Gregson A**, Kaldas F, Rubin Z, Kim T, Kunz D, Chan A, Lee DJ, Humphries RM, McKinnell JA. Practical methods for effective vancomycin-resistant enterococci (VRE) surveillance: experience in a liver transplant surgical intensive care unit. *Infection Control & Hospial Epidemiology* **2018** Oct; 39(10):1178–1182.
- [40] Shino MY, Weigt SS, Derhovanessian A, Sayah DM, Saggar R, Hyunh RH, **Gregson AL**, Ardehali A, Ross DJ, Lynch III JP, Elashoff RM, Belperio JA. The Prognostic Importance of Bronchoalve-olar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction. *American Journal of Transplantation* **2018** Jan; 18(1):136–144.
- [41] Palchevskiy V, Xue YY, Kern R, Weigt SS, **Gregson AL**, Song XS, Fishbein MC, Hogaboam CM, Sayah DM, Lynch III JP, Keane MP, Brooks DG, and Belperio JA. CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection. *JCl Insight* **2019** Jun; 4(12):e121782.

Publications—Research Papers—Peer Reviewed (Submitted)

[1] **Gregson AL**, Hoji A, Poynter S, Briones C, Belperio J. Multiparameter Flow Cytometric Characterization of Bronchoalveolar Lavage Lymphocytes for Investigating Post-Lung Transplant Alloimmune Mechanisms. *Journal of Visualized Experiments*

Publications—Research Papers—non-Peer Reviewed

[1] **Gregson AL**, Wang HH. Aliphatic Alcohols, Local and General Anesthetics and the Nicotinic Acetylcholine Receptor; a Kinetic Binding Analysis to Characterize Ion-Channel non-Competitive Binding Sites. *Senior Thesis*, University of California, Santa Cruz, **1992**.

Publications-Chapters

- [1] **Gregson AL**, Mackowiak PA. Pathogenesis of Fever. In: *Infectious Diseases*, Second Edition, Cohen J, Powderly WG (ed.), Elsevier Limited, Philadelphia, **2004**, p853–859.
- [2] Pegues DA, Kubak BM, Maree CL, **Gregson AL**. Infections in Kidney Transplantation. In: *Handbook of Kidney Transplantation*, Fifth edition, Danovitch GM (ed.), Lippincott Williams & Wilkins, Philadelphia, **2010**, p251–79.
- [3] **Gregson AL**, Mackowiak PA. Pathogenesis of Fever. In: *Infectious Diseases*, Third Edition, Cohen J, Powderly WG (ed.), Elsevier Limited, Philadelphia, **2010**, p673–678. Google Scholar Cites: 4

Publications—Reviews

- [1] **Gregson AL**, Edelman RA. Dengue Virus Infections. *Pediatric Infectious Disease Journal* **2003** Feb; 22(2):179–181. EFn: 2.9 Al 1.1 JIF: 2.723 Google Scholar Cites: 28 Scopus Cites: 12
- [2] **Gregson AL**, Edelman RA. Does Antigen Overload Exist? *Immunology Allergy Clinics of North America* Vaccines in the 21st Century, **2003** Nov; 23(3):649–664. EFn: 0.3 Al 0.8 JIF: 1.818 Google Scholar Cites: 31 Scopus Cites: 15
- [3] **Gregson AL**. Book Review of Communicable Disease Control in Emergencies: A Field Manual. *Annals of Internal Medicine* **2007** Apr 3; 146(7):544. EFn: 11.3 Al: 7.4 JIF: 17.810

- [4] Weigt SS, **Gregson AL**, Deng JC, Lynch JP, Belperio JA. Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. *Seminars in Respiratory and Critical Care Medicine* **2011** Aug; 32(4):471–93. PMC4209842 EFn: 0.5 Al: 0.8 JIF: 2.712 Google Scholar Cites: 70 Scopus Cites: 21
- [5] McKinnell JA, Cannella AP, Injean P, **Gregson AL**. Adjunctive Glucocorticoid Therapy for Non-HIV related Pneumocystis carinii Pneumonia (NH-PCP). *American Journal of Transplantation* **2014** Mar; 14:982–983. PMC4167736 EFn: 5.9 Al: 2.0 JIF: 5.683 Google Scholar Cites: 7 Scopus Cites: 2
- [6] **Gregson AL**. Lung Allograft Injury: Need for Different Police for Every Breath They Take. *International Society for Heart & Lung Transplantation Links* **2014** Jul; 6(3). http://www.ishlt.org/ContentDocuments/2014JulLinks_Gregson.html
- [7] Gregson AL. Infectious Triggers of Chronic Lung Allograft Dysfunction. *Current Infectious Disease Reports* 2016 Jun; 18(7). EFn: 0.4 Al: 1.4 JIF: 1.677 Google Scholar Cites: 11

Publications-Abstracts

- [1] Djimdé AA, Toure AM, **Gregson AL**, Beavogui A, Dao A, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Kone A, Plowe CV and Doumbo OK. Sulfadoxine-pyrimethamine treatment selects mutant but poorly infectious gametocytes of *P. falciparum* in Kolle, Mali. *NIAID International Centers for Tropical Disease Research*, Eleventh Annual Meeting, **2003**.
- [2] **Gregson AL**, Nardin E, Oliveira G, Othoro-Watta C, Calvo-Calle M, Birkett A, Edelman R. Phase I trial of Malariavax, a recombinant hepatitis B virus core particle containing repeat and T cell epitopes of the *Plasmodium falciparum* circumsporozoite protein. *American Society of Tropical Medicine and Hygiene* 53rd Annual Meeting, Featured Abstract, Abstract #922, 2004 (*American Journal of Tropical Medicine & Hygiene* **2004** Oct; 71(4):S273).
- [3] Djimdé A, Toure AM, **Gregson A**, Beavogui A, Sangare CO, Dao A, Traore Z, Maiga H, Fofana B, Coulibaly B, Tekete M, Sacko A, Ouologuem D, Niare O, Wele M, Plowe CV, Doumbo O. Sulfadoxine-Pyrimethamine treatment reduces malaria transmission in a setting of high Sulfadoxine-Pyrimethamine efficacy of Mali. *American Society of Tropical Medicine and Hygiene* 53rd Annual Meeting, Abstract #112, 2004 (*American Journal of Tropical Medicine & Hygiene* **2004** Oct; 71(4):S34).
- [4] Watta CO, Oliveira GA, Calvo-Calle M, Boehmer G, Kremsner PG, Thornton GB, Edelman R, **Gregson A**, Nardin EH. Human malaria-specific IFN-Gamma T cell responses induced by virus like particles, comprised of hepatitis B virus core antigen and P. falciparum circumsporozoite protein T and B cell epitopes (ICC-1132), adjuvanted with alum as compared to ISA 720. *American Society of Tropical Medicine and Hygiene* 55th Annual Meeting, Abstract #1101, 2006 (*American Journal of Tropical Medicine & Hygiene* 2006 Nov; 75(5):S318–319).
- [5] Mossanen M, Cruz, D, **Gregson A**, Krutzik P. Phosphoproteomic Immune Profiling in Orthotopic Heart Transplant Recipients. *American Federation of Medical Research* Annual Meeting, Abstract #339 2008 (*Journal of Investigative Medicine* **2008** Jan; 56(1):216).
- [6] **Gregson AL**, Weigt S, Elashoff R, Yang O, Belperio J. The CCR7 Ligand CCL21 Recruits CCR7⁺ Treg Population to the Lung Allograft that Prevents Development of Bronchiolitis Obliterans Syndrome. *International Society of Heart and Lung Transplantation* 29th Annual Meeting, Featured Abstract, Abstract #144, 2009, Paris. (*Journal of Heart and Lung Transplantation* **2009** Feb; 28(2):S115–116).
- [7] Saggar R, Belperio JA, Saggar R, Hunter C, Weigt SS, Lynch JP, Zisman DA, **Gregson A**, Kubak B, Lackey S, Ross DJ, Ardebali A. Intraoperative Versus Postoperative Rabbit Anti-Thymoglobulin

Globulin induction for Bilateral Lung Transplantation: A Single Center Randomized Double Blind Placebo Controlled Trial. *International Society of Heart and Lung Transplantation* 29th Annual Meeting, Abstract #684, 2009 (*Journal of Heart and Lung Transplantation* **2009** Feb; 28(2):S303).

- [8] Saggar R, Saggar R, Khanna D, Furst DE, Belperio J, Weigt S, Zisman DA, Clements PJ, Ardehali A, Kubak B, **Gregson A**, Lynch JP, Ross D. Systemic Sclerosis and Lung Transplantation: A Single Center Experience. *Arthritis and Rheumatism* **2008** Sep; 58(9):S624.
- [9] DerHovanessian A, Weigt S, Xue Y, Ardehali A, **Gregson AL**, Kubak B, Fishbein M, Saggar R, Saggar R, Ross DJ, Lynch JP, Zisman DA, Elashoff RM, Belperio JA. Primary Graft Dysfunction is Associated with BOS and Survival Following Lung Transplantation. *American Thoracic Society* May **2009**.
- [10] Palchevskiy V, Xue YY, Kern R, Weigt SS, Hu S, Derhovanessian A, Song SX, **Gregson A**, Elashoff R, Lynch JP, Belperio JA. The Role of CCR4 during the Pathogenesis of Murine Obliterative Bronchiolitis Post-Transplantation. *International Society of Heart and Lung Transplantation* 30th Annual Meeting, Abstract #394 2010 (*Journal of Heart and Lung Transplantation* **2010** Feb; 29(2):S131).
- [11] **Gregson A**, Wang X, Weigt SS, Elashoff R, Ross D, Kubak B, Saggar R, Ardehali A, Li G, Belperio J. Pseudomonas Infection Increases CXC Chemokines, Risk of BOS and Death in Lung Transplantation. *International Society of Heart and Lung Transplantation* 32th Annual Meeting, Abstract #316, 2012, Prague. (*Journal of Heart and Lung Transplantation* **2012** April; 31(4):S113).
- [12] Hsiue PP, McKinnell JA, Injean P, Toppen W, Sareh S, Vangala S, **Gregson A**, Benharash P. Selection of Antibiotic Prophylaxis for Coronary Artery Bypass Graft (CABG) Procedures in an Era of Rising MRSA Prevalence: A Survey of Current Clinical Practices in the State of California. *Academic Surgical Congress*, Abstract #ASC20140471, San Diego, California. **2014**.
- [13] DerHovanessian A, Li N, Shino M, Sayah DM, **Gregson AL**, Lynch III JP, Saggar R, Ardehali A, Ross DJ, Elashoff RM, Weigt S. Defining clinically relevant CLAD phenotypes in bilateral and single lung transplant recipients. *International Society of Heart and Lung Transplantation* 34th Annual Meeting, Abstract #96, 2014. (*Journal of Heart and Lung Transplantation* **2014**;33(4):S42 10.1016/j.healun.2014.01.144).
- [14] Linfield R, Injean R, Miller S, de Shadarevian M, **Gregson AL**, Li H, Bangayan N, Kaldas F, Do JY, Keckeisen M, Donovan M, Duli L, Rubin Z, Kim T, Eells S, Benharash P, Humphries R, McKinnell JA. Accuracy versus Convenience in Surveillance for VRE and CRE. Abstract #19. Josiah Brown Poster Fair, David Geffen School of Medicine at UCLA. Los Angeles, California, **2015** July 24.
- [15] Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Saggar R, Lynch JP, Ross DJ, Ardehali A, Belperio JA, Tseng CH, **Gregson AL**. Viral Pneumonia Accelerates Graft Death and CLAD in Lung Transplant Recipients. *International Society of Heart and Lung Transplantation* 35th Annual Meeting, Abstract #839, 2015 (*Journal of Heart and Lung Transplantation* **2015** 34(4):S305 10. 1016/j.healun.2015.01.858).
- [16] Kassamali Z, Curello J, **Gregson AL**. Comparison of Continuous versus Intermittent Intravenous Infusion of Colistimethate Sodium (Colistin) for Treatment of Carbapenem-Resistant Gram Negative Bacterial Infections. *26th ECCMID Congress, the European Congress of Clinical Microbriology and Infectious Diseases*, Amsterdam, The Netherlands, Abstract #6422, Presentation #1230, April **2016**.
- [17] Linfield R, Injean P, Miller S, Kaldas F, Rubin Z, Kim T, Eells JS, **Gregson AL**, Humphries R, McKinnell JA. Improved VRE Surveillance Detects Patients at Risk for Subsequent VRE Infection. *The Society for Healthcare Epidemiology of America* **2016** *Spring Conference*, Atlanta, GA. Abstract #7922.

- [18] Linfield R, Miller S, Injean P, **Gregson AL**, Kaldas F, Rubin Z, Kim T, Eells S, Humphries R, McKinnell JA. Surveillance for CRE Colonization Yields Detection of Unexpected Resistance Patterns. *The Society for Healthcare Epidemiology of America* **2016** *Spring Conference*, Atlanta, GA.
- [19] Gaut D, Cone BD, **Gregson AL**, Agopian VG. A case of gastrointestinal mucormycosis following orthotopic liver transplantation presenting as a femoral neve palsy. **2016** American College of Physicians Southern California Chapters Poster Competition, San Diego, CA.
- [20] Mckinnell JA, Eells SJ, Injean P, Whang D, Humphries R, **Gregson AL**. Linezolid versus Daptomycin in the Treatment of Vancomycin-resistant Enterococcal bloodstream infection (VRE-BSI) at a Transplant center. *IDWeek* **2016** Abstract #2019, New Orleans, LA.
- [21] **Gregson AL**, Grotts JF. Acute Rejection Interaction with Viral Pneumonia Augments CLAD Risk. International Society of Heart and Lung Transplantation 37th Annual Meeting **2017** Abstract #0990, San Diego, CA.
- [22] **Gregson AL**. CMV in Thoracic Organ Transplantation—A Discussion of the Ever Changing Landscape. *International Society of Heart and Lung Transplantation* 38th Annual Meeting **2018** Symposium Proposal Accepted, Nice, France.